# LONA catalysts: LeonaBio, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lona/catalysts

> LeonaBio, Inc. (LONA) has 6 upcoming catalysts. The next is the lasofoxifene in combination with abemaciclib primary completion, April 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | LeonaBio, Inc. |
| Ticker | LONA (Nasdaq) |
| SEC CIK | 1620463 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/lona |

## Cash runway

Cash $51.1M as of 2026-06-30; quarterly burn $17.0M; about 9.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-352243).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [Fosgonimeton topline data readout](https://sec-api.dev/pdufa/fosgonimeton) | LONA |  | completed, missed | "In September 2024, we announced the topline results for LIFT-AD, showing that the trial did not meet its primary or key secondary endpoints." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1620463/000095017025029069/atha-20241231.htm)) |
| February 27, 2025 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000095017025029038/atha-ex99_1.htm)) |
| May 9, 2025 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/atha-ex99_1.htm)) |
| August 7, 2025 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/atha-ex99_1.htm)) |
| November 6, 2025 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm)) |
| early 2026 | [Brelgometon trial start](https://sec-api.dev/pdufa/brelgometon) | LONA |  | scheduled | "LeonaBio plans to initiate a Phase 2 clinical trial of ATH-1105 in ALS patients in early 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/atha-ex99_1.htm)) |
| 2026 | [LeonaBio, Inc. topline data readout](https://sec-api.dev/companies/lona/catalysts) | LONA |  | scheduled | "The Phase 2a trial in people living with ALS has an anticipated start in 2026, with topline results expected as early as 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1620463/000119312525323692/atha-20251218.htm)) |
| March 26, 2026 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526126579/lona-ex99_1.htm)) |
| May 7, 2026 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526211867/lona-ex99_1.htm)) |
| June 30, 2026 | [Inluriyo™ (imlunestrant) complete response letter (CRL)](https://sec-api.dev/pdufa/imlunestrant) | LONA |  | completed, complete response letter | "The Series A Common Warrants have an exercise price of $6.35 per share and are exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Company publicly announces the enrollment of the 500th subject or the last subject, whichever is earlier, in the ELAINE-3 trial; and (c) the date on which the FDA approves or issues a complete response letter to Eli Lilly & Co.'s marketing application, including a supplement to a new drug application, for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 ( the "Series A Common Warrant Initial Exercise Date")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352243/lona-20260630.htm)) |
| June 30, 2026 | [LeonaBio, Inc. topline data readout](https://sec-api.dev/companies/lona/catalysts) | LONA |  | scheduled | "The PIPE Series B Common Warrants will have an exercise price of $7.62 per share payable on a cashless net exercise basis, subject to adjustments as provided therein, and will be exercisable, subject to the restrictions discussed below, after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the ELAINE-3 Trial (the later of (1) and (2), the "Series B Common Warrant Initial Exercise Date")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1620463/000119312525323692/atha-20251218.htm)) |
| August 14, 2026 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/lona-ex99_1.htm)) |
| April 2027 | [Lasofoxifene in combination with abemaciclib primary completion](https://sec-api.dev/pdufa/lasofoxifene-in-combination-with-abemaciclib) | LONA | Metastatic Breast Cancer | scheduled | "NCT05696626 (Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor LeonaBio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05696626)) |
| Apr to Jul 2027 | [Lasofoxifene in combination with abemaciclib topline data readout](https://sec-api.dev/pdufa/lasofoxifene-in-combination-with-abemaciclib) | LONA | Metastatic Breast Cancer | scheduled | "NCT05696626 (Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor LeonaBio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05696626)) |
| 2H 2027 | [LeonaBio, Inc. topline data readout](https://sec-api.dev/companies/lona/catalysts) | LONA |  | scheduled | "The Company expects to complete enrollment of the Phase 3 ELAINE-3 clinical trial in the fourth quarter of 2026 and to have topline data in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526211867/lona-ex99_1.htm)) |
| 2H 2027 | [Lasofoxifene topline data readout](https://sec-api.dev/pdufa/lasofoxifene) | LONA |  | scheduled | ""We have enrolled 495 patients and remain on track to complete enrollment of ELAINE-3 in the fourth quarter of 2026 with topline data expected in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/lona-ex99_1.htm)) |
| 2H 2027 | [LeonaBio, Inc. topline data readout](https://sec-api.dev/companies/lona/catalysts) | LONA |  | scheduled | "OVER 50% ENROLLED - EXPECTED TO READOUT IN 2H2027 Global study with >200 sites Europe, North America, and APAC (including China) Study is being executed by Medpace, a full-service global CRO with extensive experience running large, successful breast cancer trials Primary endpoint is determined by an independent review of centralized scans using industry standard RECIST criteria Primary readout conducted when 285 patients have been determined as meeting the RECIST criteria for progression ELAINE-3 is on track to complete enrollment in 2H2026 © LeonaBio, Inc." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526126579/lona-ex99_2.htm)) |
| 2H 2027 | [Brelgometon topline data readout](https://sec-api.dev/pdufa/brelgometon) | LONA |  | scheduled | "Expected key inflection points within ~2 years Lasofoxifene Phase 3 registrational study ongoing with >50% enrolled ATH-1105 Phase 2 POC study in ALS planned to start in 2H2026 Topline results expected in 2H2027 Topline results expected 2027 © LeonaBio, Inc." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526126579/lona-ex99_2.htm)) |

## Drugs

- [Brelgometon](https://sec-api.dev/pdufa/brelgometon): 
- [Fosgonimeton](https://sec-api.dev/pdufa/fosgonimeton): 
- [Lasofoxifene](https://sec-api.dev/pdufa/lasofoxifene): 
- [Lasofoxifene in combination with abemaciclib](https://sec-api.dev/pdufa/lasofoxifene-in-combination-with-abemaciclib): Metastatic Breast Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lona/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LONA catalysts: LeonaBio, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lona/catalysts

```bibtex
@misc{secapidev_companies_lona_catalysts_20261116,
  title        = {LONA catalysts: LeonaBio, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lona/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lona_catalysts_20261116","title":"LONA catalysts: LeonaBio, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lona/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
